NCT01678690View on ClinicalTrials.gov

An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Malignant Tumors
Interventions
DRUG

Gemcitabine HCl Oral Formulation

Gemcitabine HCl Oral Formulation 80 mg/vial Subjects will be treated on Day 1 of the 7-day study treatment period

Trial Locations (4)

10048

National Taiwan University Hospital, Taipei

30912

Georgia Regents University- Cancer Center, Augusta

44622

Gabrail Cancer Center Research, Dover

44718

Gabrail Cancer Center Research, Canton

Sponsors

Lead Sponsor

InnoPharmax Inc.
All Listed Sponsors
lead

InnoPharmax Inc.

INDUSTRY

NCT01678690 - An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors | Biotech Hunter | Biotech Hunter